Phase 1, Open-Label, Safety, Reactogenicity, and Immunogenicity Trial of RVX-sCPD9, a live-attenuated SARS-CoV-2 virus, as a Booster Vaccine, Via the Intranasal Route, in Previously Vaccinated Adults